In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Gender differences in heart failure with mid-range ejection fraction patients

Session Poster Session 1

Speaker Jung-Hyun Choi

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : J-H Choi (Busan,KR), JC Choi (Busan,KR)

Authors:
J-H Choi1 , JC Choi1 , 1Busan National University Hospital - Busan - Korea (Republic of) ,

Citation:

Background: Little is known on the gender differences in patients with heart failure (HF) with mid-range ejection fraction (EF) (HFmrEF).

Objectives: We aimed to investigate the gender differences in patients with HFmrEF.

Methods: Among 252 consecutive patients with primary diagnosis of HFmrEF (EF 40-49%) and baseline and follow-up echocardiogram in an urban tertiary referral center from October 2013 to March 2017, 131 (52.0%) were in men and 121 (48.0%) were in women. We compared the characteristics and composite event (cardiovascular death and HF readmission).

Results: Compared to women, men had significantly higher rates of prior ischemic heart disease, chronic kidney disease (CKD), and peripheral arterial disease. At baseline, LVEF was not significantly different between men and women. At follow-up, LVEF in women significantly improved from the baseline levels (48.9% vs. 45.3%, p<0.001), whereas no significant changes in LVEF were observed in men. In women, the use of inhibitor of the renin angiotensin system (odds ratio 0.39, 95% confidence interval [CI] 0.18-0.82, p=0.014) was contributed to the improvement of LVEF. Composite event occurred in 80 patients (31.7%). There were no significant differences in the composite event between men and women (32.1% vs. 31.4%, hazard ratio [HR] 1.16, 95% CI 0.74-1.81, p=0.529). Significant contributors for composite event were age (HR 1.04, 95% CI 1.01-1.06, p=0.002), the presence of atrial fibrillation (HR 1.78, 95% CI 1.15-2.76, p=0.010), spironolactone use (HR 0.56, 95% CI 0.36-0.87, p=0.009). Cardiac death occurred in 9 patients (3.6%). Men had a significantly higher rate of cardiac death than women (6.1% vs. 0.8%, HR 1.26, 95% CI 1.01-6.69, p=0.027). In men, age (HR 1.12, 95% CI 1.02-1.22, p=0.015) and CKD (HR 3.14, 95% CI 1.03-6.58, p=0.042) were independently predictive for increased risk of cardiac death.

Conclusions: This study showed that in patients with HFmrEF, women might be associated with improved LVEF and lower risk of cardiac death compared to men.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are